טוען...
Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
BACKGROUND: Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-naive children, Aged 1–17 years, with pulmonary arte...
שמור ב:
| הוצא לאור ב: | BMC Cardiovasc Disord |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5496590/ https://ncbi.nlm.nih.gov/pubmed/28676038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-017-0569-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|